FDA approves first treatment for acquired TTP

Author(s):

treatment acquired ttp

On Feb. 6, the FDA approved Cablivi (caplacizumab-yhdp) injection, the first therapy indicated, in combination with plasma exchange and immunosuppressive therapy, for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP).

Read more via U.S. Food & Drug Administration.

LEAVE A REPLY

Please enter your comment!
Please enter your name here